Health Affairs, 27, no. 6 (2008): 1599 doi: 10.1377/hlthaff.27.6.1599 © 2008 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Research And Technology Health Spending

Genomics

PROLOGUE

Genomics

The mapping of the human genome has created the opportunity for early identification of those at risk for a wide range of common, life-threatening diseases. The pace of discovery in the field of genomic research has been accompanied by expectations that cutting-edge, individualized treatments—so-called personalized medicine—may be just around the corner.

A fundamental question for stakeholders—researchers, policymakers, and consumers alike—is whether these genomic discoveries are useful and can be translated into actual health care interventions that can practically and cost-effectively find their way into hospitals and doctors’ offices.

But how much evidence should be required to show that a discovery . . . [Full Text of this Article]

                      What's this?